Search Results
Your search for ,dUe matches 5584 pages
Showing 5251 - 5300ASH 2014: HIV-Related Lymphoma Can Be Safely Treated With Autologous Hematopoietic Cell Transplant
Patients with human immunodeficiency virus (HIV)-related relapsed/refractory lymphoma can safely undergo autologous hematopoietic cell transplant, according to results of a phase II multicenter trial. At many centers, patients with HIV-related lymphoma are currently excluded from this potentially...
ASH 2014: Strong Showing for Anti-CD38 Monoclonal Antibodies in Myeloma
An investigational new class of drugs, the anti-CD38 monoclonal antibodies, could be the next blockbuster agents in multiple myeloma, experts in this malignancy predicted at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. Anti-CD38 antibodies target multiple myeloma...
ASH 2014: Carfilzomib-Based Triplet Yields ‘Unprecedented’ Duration of Remission in Relapsed Myeloma
The phase III global ASPIRE trial documented an “unprecedented” duration of remission in relapsed multiple myeloma patients receiving carfilzomib (Kyprolis) plus a standard-of-care doublet, according to A. Keith Stewart, MD, of the Mayo Clinic in Scottsdale, Arizona, who presented the...
Dacomitinib Shows Activity in First-Line Treatment of Patients With Clinically or Molecularly Selected Advanced NSCLC
In a phase II trial reported in The Lancet Oncology, Jänne et al found that the pan-HER inhibitor dacomitinib was active in first-line treatment of patients with advanced non–small cell lung cancer (NSCLC) with EGFR mutations or clinical characteristics associated with response to EGFR...
High-Dose Interleukin-2 Effective in Metastatic Renal Cell Cancer Pretreated With VEGF-Targeted Therapies
High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pretreated with VEGF-targeted agents, according to research presented recently at the ESMO Symposium on Immuno-Oncology in Geneva (Abstract 4O). “Despite the wide and increasing range of therapies...
Cigarette Smoking Before Diagnosis of First Cancer Is Associated With Increased Risk of Second Cancers
In a study reported in the Journal of Clinical Oncology, Shiels et al found that prediagnostic smoking among survivors of stage I lung cancer or bladder, kidney, or head/neck cancer was associated with increased risk of second lung, bladder, kidney, and head and neck cancer. Study Details The...
Advanced-Practice Nurse Telephone Counseling Improves Rate of Cardiomyopathy Screening in At‑Risk Adult Survivors of Pediatric Cancer
In the ECHOS trial reported in the Journal of Clinical Oncology, Hudson et al found that the addition of two tailored telephone counseling sessions by an advanced-practice nurse to a mailed personalized survivorship care plan including cardiac screening recommendations resulted in a greater than...
Researchers Identify Biomarker of Response to New Ovarian Cancer Drug
Researchers have found a way to identify which ovarian cancer patients are likely to respond well to a new anticancer drug called rucaparib. Previous clinical trials have shown that women with platinum-sensitive tumors with BRCA1/2 mutations respond well to rucaparib. In new findings presented...
About 25% of Patients Undergoing Breast-Conservation Surgery for Stage 0 to II Carcinoma Have Subsequent Surgery
“Approximately one-fourth of all patients who undergo initial breast-conservation surgery for breast cancer will have a subsequent operative intervention,” concluded a study published online in JAMA Surgery. “The rate of repeat surgeries varies by patient, tumor, and facility...
Galeterone Shows Activity in Variant Form of Castration-Resistant Prostate Cancer
Results from the ARMOR2 of the anticancer drug galeterone shows that it is successful in lowering prostate-specific antigen (PSA) levels in men with a variant form castration-resistant prostate cancer. The findings, presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer...
Metabolic ‘Reprogramming’ by the p53 Gene Family Leads to Tumor Regression
Scientists have found that altering members of the p53 gene family, known as tumor-suppressor genes, causes rapid regression of tumors that are deficient in or totally missing p53. Study results suggest existing diabetes drugs, which impact the same gene-protein pathway, might be effective for...
Outcomes With Lobectomy, Sublobar Resection, and Stereotactic Ablative Radiotherapy in Medicare Patients With Early-Stage NSCLC
In a study on use of the most common definitive therapies for non–small cell lung cancer (NSCLC) in Medicare patients reported in JAMA Surgery, Shirvani et al found that lobectomy was associated with improved outcome vs sublobar resection and that stereotactic ablative radiotherapy may be of...
Worse Patient-Reported Outcomes With Addition of Ovarian Function Suppression to Tamoxifen in Premenopausal Women With Breast Cancer
In the phase III Eastern Cooperative Oncology Group (ECOG) E-3193 (Intergroup 0142) trial, reported in the Journal of Clinical Oncology by Tevaarwerk et al, adding ovarian function suppression to tamoxifen was associated with worse patient-reported outcomes in premenopausal women with...
Olaparib Treatment Yields Promising Response Rates in Patients With BRCA Mutation–Associated Cancers
Olaparib, an experimental twice-daily oral cancer drug, produced an overall tumor response rate of 26% in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to a phase II study reported by Kaufman et al in the Journal of Clinical Oncology. The positive response provides...
No Benefit of Adding Lapatinib to Fulvestrant in Hormone Receptor–Positive Advanced Breast Cancer
In the phase III Cancer and Leukemia Group B (CALGB) 40302/Alliance trial reported in the Journal of Clinical Oncology, Burstein et al found that the addition of the dual EGFR-HER2 inhibitor lapatinib (Tykerb) to endocrine therapy with fulvestrant (Faslodex) did not improve progression-free...
Comparable Disease Control, Less Morbidity With Axillary Radiotherapy vs Surgery in Breast Cancer Patients With Positive Sentinel Node
In a noninferiority phase III EORTC 10981-22023 AMAROS trial reported in The Lancet Oncology, Donker et al found that axillary radiotherapy provided comparable disease control and was associated with less morbidity compared with axillary surgery in breast cancer patients with a positive sentinel...
FOLFOXIRI/Bevacizumab Bests FOLFIRI/Bevacizumab in Metastatic Colorectal Cancer
Patients with untreated metastatic colorectal cancer who received FOLFOXIRI (fluorouracil [5-FU], leucovorin, oxaliplatin, irinotecan) plus bevacizumab (Avastin) had improved survival compared to patients who received FOLFIRI (5-FU, leucovorin, irinotecan) plus bevacizumab in a phase III...
New Guidelines Issued on Use of Complementary Therapies for Breast Cancer
More than 80% of breast cancer patients in the United States use complementary therapies following a breast cancer diagnosis, but there has been little science-based guidance to inform clinicians and patients about their safety and effectiveness. In newly published clinical practice guidelines...
Absence of Residual Thrombosis After 6 Months of Low–Molecular Weight Heparin Indicates Low Risk for Recurrent Cancer-Related Deep-Vein Thrombosis
In an Italian study (Cancer-DACUS) reported in the Journal of Clinical Oncology, Napolitano et al found that patients with no residual vein thrombosis after 6 months of low–molecular weight heparin for a first episode of cancer-related deep-vein thrombosis of the lower limbs had low risk for...
Cancer Leaders Call for Congress to Act Quickly in 2015 to Reinvigorate Cancer Innovation in the United States
Even before the next Congress is formally elected, a national group of health-care stakeholders called the Cancer Innovation Coalition (CIC) went to Capitol Hill today to call for early legislative and regulatory action in 2015 that will reinvigorate cancer innovation in the United States. The...
Performance of Lung Cancer Low-Dose CT Screening With Increasing Screening Interval in NELSON Trial
The Dutch and Belgian NELSON trial is assessing the effect of increasing interval low-dose computed tomography (CT) screening for lung cancer on lung cancer mortality. In an analysis of screening test performance among Dutch participants reported in Lancet Oncology, Horeweg and colleagues found...
New Research Shows Association of Kidney Cancer With Use of Aristolochic Acid
New research by the international Cancer Genomics of the Kidney consortium (CAGEKID) reveals an important connection between kidney cancer and exposure to aristolochic acid, an ingredient in some herbal remedies. The findings, published by Scelo et al in Nature Communications, have important...
Topical Cidofovir and Imiquimod Active in Treating Vulval Intraepithelial Neoplasia
In a UK phase II trial reported in The Lancet Oncology, Tristram et al found that topical cidofovir and topical imiquimod were active in the treatment of vulval intraepithelial neoplasia, suggesting that such treatment may constitute an alternative to surgery. Study Details In the open-label...
Chest Radiation to Treat Childhood Cancer Increases Patients’ Risk of Developing Breast Cancer
A new study has found that patients who received chest radiation for Wilms tumor, a rare childhood cancer, face an increased risk of developing breast cancer later in life due to their radiation exposure. Reported by Lange et al in Cancer, the findings suggest that cancer screening guidelines might ...
One-Third of U.S. Cancer Survivors May Be Experiencing Financial or Work-Related Hardship
New results from a survey of nearly 1,600 cancer survivors indicate a high prevalence of financial and work-related difficulties: 27% reported at least one financial problem (eg, debt, bankruptcy), and 37% reported having to modify work plans, such as taking extended time off or delaying...
First-Line FOLFIRI Improves Time to Treatment Failure and Is Better Tolerated vs ECX in Advanced Gastric Cancer
In a phase III French Intergroup trial reported in the Journal of Clinical Oncology, Guimbaud et al found that FOLFIRI (fluorouracil [5-FU], leucovorin, and irinotecan) significantly prolonged time to treatment failure compared with ECX (epirubicin, cisplatin, and capecitabine) in first-line...
Newly Discovered Molecular-Level Mechanism May Increase the Growth of Breast Cancer Cells
Researchers at VTT Technical Research Centre of Finland, the University of Turku, Finland, and the University of Oslo, Norway, have discovered a previously unknown molecular-level mechanism that may partly explain the increased growth of cancer cells. The study, published in the British Journal of...
Study Finds Increased Expression of NQO1 in Non–Small Cell Lung Cancer Patients With KRAS Mutations
In smokers with non–small cell lung cancer (NSCLC), the relationship between KRAS mutations and NQO1 may be of future therapeutic value, according to the study findings presented by Yilmaz et al in the International Journal of Environmental Research and Public Health. The researchers...
ASCO Issues Clinical Expert Statement on Cancer Survivorship Care Planning
Efforts at implementing survivorship care plans have met with limited success in oncology practice, in part due to the time required to complete survivorship care plans, lack of role clarity, and lack of reimbursement for time to complete the documents. In response, ASCO convened a Survivorship...
CD19-Directed CAR T Cells Produce Sustained Remission in Relapsed/Refractory ALL
In a study reported in The New England Journal of Medicine, Maude et al reported achieving sustained remissions in children and adults with relapsed/refractory acute lymphoblastic leukemia (ALL) using autologous CD19-targeted chimeric antigen receptor (CAR)-modified T cells. Study Details In the...
Having Dependent Children Motivates Parents With Advanced Cancer to Pursue More Aggressive, Life-Extending Treatments
Findings from a pilot study of 42 parents with advanced cancer indicate that parental status is an important factor in treatment decision-making. When asked how having children influences their treatment decisions, the majority of parents (64%) responded that being a parent motivates them to pursue ...
Second-Line Bevacizumab/Chemotherapy Improves Progression-Free Survival in Advanced HER2-Negative Breast Cancer
In the phase III TANIA trial reported in The Lancet Oncology, von Minckwitz et al found that adding bevacizumab (Avastin) to chemotherapy in second-line treatment improved progression-free survival after first-line bevacizumab plus chemotherapy in patients with HER2-negative locally recurrent or...
New Findings in Acute Promyelocytic Leukemia
Three studies reported in the Journal of Clinical Oncology provide information on maintenance treatment with the synthetic retinoid tamibarotene in acute promyelocytic leukemia, potential implications of QT interval prolongation related to arsenic trioxide (Trisenox), and potential health-related...
Improved Survival With Maintenance Capecitabine/Bevacizumab vs Bevacizumab Alone in HER2-Negative Metastatic Breast Cancer
Regulatory approval of bevacizumab (Avastin) plus docetaxel in metastatic breast cancer was withdrawn in Europe in February 2011 and in the United States in November 2011. The phase III IMELDA trial comparing maintenance capecitabine/bevacizumab vs bevacizumab after first-line bevacizumab/docetaxel ...
One in Three People With Cancer Has Anxiety or Other Mental Health Challenges
Researchers in Germany report that nearly one-third of more than 2,100 patients with cancer interviewed at inpatient and outpatient care centers experienced a clinically meaningful level of mental or emotional distress that meets the strict diagnostic criteria for mental disorders including...
Abiraterone Acetate/Prednisone in Metastatic Castration-Resistant Prostate Cancer: Final Analysis of Early-Access Protocol Study
Abiraterone acetate (Zytiga) is approved for use in combination with prednisone in the treatment of metastatic castration-resistant prostate cancer. As reported by Sternberg et al in The Lancet Oncology, results of an open-label, early-access protocol trial initiated prior to approval indicated no...
Dutch Study Finds No Increased Risk of Cardiovascular Mortality in 5-Year Survivors of DCIS
In a Dutch study reported in the Journal of the National Cancer Institute, Boekel et al found no increase in risk of cardiovascular mortality among 5-year survivors of ductal carcinoma in situ (DCIS) compared with the general population. Among DCIS patients, risk of cardiovascular events did not...
ESMO 2014: Phase III Study Confirms Regorafenib’s Survival Benefit in Metastatic Colorectal Cancer
The phase III CONCUR trial of regorafenib (Stivarga) monotherapy in Asian patients with previously treated metastatic colorectal cancer confirmed the overall survival benefit seen in the previous CORRECT trial and in an exploratory analysis suggested the benefit is substantial in patients not...
Boost in Plasma Levels of Chain Amino Acids Is Associated With Increased Risk of Pancreatic Cancer
In a recent study reported in Nature Medicine, scientists from Dana-Farber Cancer Institute, the Massachusetts Institute of Technology, and the Harvard School of Public Health, among other institutions, investigated whether pancreatic ductal adenocarcinoma produces metabolic changes that can be...
Safe Integration of Surgical Innovations Essential to Patient Safety: Study Evaluates Minimally-Invasive Radical Prostatectomy
In the introduction to a cohort study reported in JAMA Surgery, Parsons et al stated “Surgical innovations disseminate in the absence of coordinated systems to ensure their safe integration into clinical practice, potentially exposing patients to increased risk for medical error.” Their ...
Pazopanib Maintenance Improves Progression-Free Survival in Ovarian Cancer, but Benefit Limited to Non–East Asian Patients
In a phase III trial reported in the Journal of Clinical Oncology, du Bois et al found that maintenance therapy with the VEGFR and PDGFR inhibitor pazopanib (Votrient) significantly prolonged progression-free survival vs placebo in women with ovarian cancer without progression after first-line...
Adding Pan-Deacetylase Inhibitor Panobinostat to Bortezomib and Dexamethasone Improves Progression-Free Survival in Relapsed Myeloma
In the phase III PANORAMA1 trial reported in The Lancet Oncology, San-Miguel and colleagues found that adding the pan-deacetylase inhibitor panobinostat to bortezomib (Velcade) and dexamethasone improved progression-free survival in patients with relapsed or relapsed and refractory multiple...
Improved Outcomes in Myeloma With High-Dose Melphalan Plus Autologous Transplant and Lenalidomide Maintenance
In a phase III trial reported in The New England Journal of Medicine, Palumbo et al found that consolidation therapy with high-dose melphalan plus autologous stem cell transplantation improved progression-free survival and overall survival compared with melphalan/prednisone/lenalidomide (Revlimid)...
ASTRO: Analysis Finds Select Group of Stage IV Lung Cancer Patient Population Achieves Long-Term Survival After Aggressive Treatment
A large, international analysis of patients with stage IV non–small cell lung cancer (NSCLC) indicates that a patient’s overall survival rate can be related to factors including the timing of when metastases develop and lymph node involvement, and that aggressive treatment for low-risk...
Anti-CD19 CAR T-Cell Treatment Effective in Chemotherapy-Refractory B-Cell Malignancies
In a study reported in the Journal of Clinical Oncology, Kochenderfer et al found that single infusions of autologous T cells expressing an anti-CD19 chimeric antigen receptor (CAR) produced responses in nearly all patients with chemotherapy-refractory CD19-positive B-cell malignancies, including...
AACR’s 2014 Cancer Progress Report Stresses Research Advances and More Federal Funding
The American Association for Cancer Research (AACR) released its 2014 Cancer Progress Report today, which highlights the quickening pace of drug development and approval, especially in molecularly targeted agents that are leading to increased numbers of cancer survivors. However, the report also...
Radiation Therapy With Concurrent Chemotherapy After Surgery Is an Effective Treatment for High-Risk Endometrial Cancer
Radiation therapy with concurrent paclitaxel chemotherapy following surgery is an effective treatment for high-risk endometrial cancer, according to a study reported by Cho et al in the International Journal of Radiation Oncology • Biology • Physics Endometrial...
ASCO Issues New Guideline on Chemotherapy and Targeted Therapy in Advanced HER2-Negative or Unknown HER2 Status Breast Cancer
The American Society of Clinical Oncology has released a new clinical practice guideline on chemotherapy and targeted therapy for women with advanced HER2-negative or unknown HER2 status breast cancer. The guideline is published in the Journal of Clinical Oncology. In formulating the consensus...
Breast Cancer Surgery and Reconstruction Complications Are Rare, but Risk of Some Complications Higher With Bilateral vs Unilateral Mastectomy
A new analysis of 30-day post-surgery complications among more than 18,000 women with breast cancer undergoing bilateral and unilateral mastectomy with breast reconstruction found that complications were generally rare for either type of surgery, with an overall rate of complications of 5.3%....
Family Physician–Signed Reminder Letters Improve Return Rates for Women Overdue for Screening Mammography
A large study conducted through the BC Cancer Agency in British Columbia, Canada, reports that adding family physician–signed reminder letters to the standard schedule of postcard reminders substantially improves return rates for screening among women who are overdue for such screening. In a...
